skinny.

Latest / Breastcancer.org Podcast

Kisqali Helps Treat Early-Stage Breast Cancer

At the 2023 American Society of Clinical Oncology Annual Meeting, Dr. Slamon presented results from the NATALEE trial, showing that Kisqali plus an aromatase inhibitor after surgery for early-stage, hormone receptor-positive, HER2-negative breast cancer, reduced recurrence risk by 25% compared to an aromatase inhibitor alone.

Listen to the podcast to hear Dr. Slamon explain:

why he thought Kisqali could benefit people with early-stage breast cancer

the side effects Kisqali can cause

what the results mean for people diagnosed with early-stage, hormone receptor-positive disease

The skinny

The skinny isn't ready yet — notes appear once the transcript is processed.